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Background: The aim of this study was to determine the osteoconductivity of hydroxyapatite particles (HAP) as a
carrier for Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2). Two 8-mm
diameter bicortical calvarial defects were created in each of 20 rabbits. One of each pair of defects was randomly
assigned to be filled with HAP only (HAP group) or ErhBMP-2 loaded HAP (ErhBMP-2/HAP group), while the other
defect was left untreated (control group). The animals were killed after either 2 weeks (n = 10) or 8 weeks (n = 10)
of healing, and histological, histomorphometric, and tomographic analyses were performed.
Results: All experimental sites showed uneventful healing during the postoperative healing period. In both
histomorphometric and tomographic analyses, the new bone area or volume of the ErhBMP-2/HAP group was
significantly greater than that of the HAP and control groups at 2 weeks (p < 0.05). However, at 8 weeks, no
significant difference in new bone area or volume was observed between the ErhBMP-2/HAP and HAP groups.
The total augmented area or volume was not significantly different between the ErhBMP-2/HAP and HAP groups
at 2 and 8 weeks.
Conclusions: Combining ErhBMP-2 with HAP could significantly promote rapid initial new bone formation.
Moreover, HAP graft could increase new bone formation and space maintenance, therefore it might be one of
the effective carriers of ErhBMP-2.
Keywords: Hydroxyapatite, Escherichia coli-derived recombinant human bone, Morphogenetic protein-2, Bone
regeneration, Tissue engineering, Calvarial intraosseous defect modelBackground
Bone augmentation is generally carried out using autogen-
ous bone, allograft, xenograft, or alloplastic materials. The
ideal bone graft includes elements that are osteogenic,
osteoinductive, and osteoconductive. Autogenous bone
contains all three types of elements, but it is not available
in every situation. Many studies have shown that xeno-
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engineering. Numerous growth factors that enhance vari-
ous types of cell migration, adherence, and proliferation
have been identified. One of these, bone morphogenetic
protein (BMP), is a multifunctional protein with a wide
range of biological activities in a variety of cell types [1].
BMPs regulate growth, differentiation, chemotaxis, and
apoptosis. They also play pivotal roles in morphogenesis
[2]. BMPs constitute the osteoinductive component of
several tissue engineering products that are used in late-
stage development as replacements for autogenous bone
grafts and for bone augmentation and repair [3]. Manyrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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(rhBMP-2) [4, 5]. However, BMP-2 derived from Chinese
hamster ovary cells (CHO BMP-2) is relatively costly be-
cause protein yields are low. In this context, our research
group recently succeeded in producing BMP-2 using an
Escherichia coli production system (ErhBMP-2), which is
particularly attractive for biotechnology because of the
ability of E. coli to grow rapidly and to high density on in-
expensive substrates [6]. Moreover, ErhBMP-2 and CHO
BMP-2 may function similarly in bone regeneration [7].
Several studies have demonstrated the efficacy of
ErhBMP-2; for example, it was shown that ErhBMP-2 fa-
cilitated closure of the bone gap of a sinus window [8] and
ErhBMP-2-coated implants enhanced bone-to-implant
contact [9]. Various carriers have been recommended, in-
cluding fibrin-fibronectin, biphasic calcium phosphate,
beta-tricalcium phosphate (β-TCP), and hydroxyapatite
(HA) [10]. The biological response to bone substitute ma-
terials depends not only on their chemical composition
but also on their macro- and microstructural characteris-
tics, including pore size, porosity, and interconnectivity
[11]. The United States Food and Drug Administration
has approved the use of BMP with an absorbable collagen
sponge as carrier. However, ErhBMP-2 can be separated
from the collagen under physical pressure, and collagen is
rapidly absorbed. The carrier needs to be able to maintain
space for subsequent bone formation. One carrier with
this ability is HA. HA is used as a bone graft extender for
posterolateral spinal fusion in humans [12]. It is also use-
ful as an ErhBMP-2 carrier because of its high affinity for
ErhBMP-2. ErhBMP-2-adsorbed hydroxyapatite particles
(HAP) are safe and can be an effective and attractive ma-
terial for bone formation, since the pore size of HAP is ap-
proximately 100–300 μm. The optimal pore size for bone
regeneration is known to be 300–400 μm. The minimal
interconnection pore size is 5–15 μm for fibrous tissue,
40–100 μm for osteoid tissue, and 100 μm for mineralized
bone. Therefore, it appears that the pore size of HAP is
suitable for promoting early bone ingrowth. Furthermore,
in another study, alkaline phosphatase activity was signifi-
cantly higher in mandibular defects treated with porous
HA and ErhBMP-2 than in controls treated with HA
alone at both 7 and 21 days [13], indicating that ErhBMP-
2 accelerated bone formation by osteoconduction from
porous HA.
β-TCP is more bioresorbable than HAP and is re-
placed by new bone at a high rate [14]. In a study that
compared changes in the distribution and expression of
biomarkers of reactogenicity in the lower jaws of rabbits
after implantation, osteoblast proliferation and regions
of granulation tissue formation were more noticeable in
experimental tissues than in the control tissue. The ex-
perimental and control groups did not differ significantly
in mean β-defensin-2, IL-1, IL-6, IL-8, IL-10, osteopontin,osteocalcin, BMP-2/4, or osteoprotegerin expression. Fur-
thermore, the prevalence of osteopontin- and osteocalcin-
positive osteocytes in experimental tissues implanted with
HAP at 3 months after implantation indicated potential
bone regeneration stimulated by pure HAP. Therefore,
the slow resorption of HAP may enhance osteoconductiv-
ity, thereby promoting new bone growth. Based on these
studies, we aimed to evaluate the effect of HAP on bone
regeneration and to determine the efficacy of HAP as a
carrier for ErhBMP-2 in the rabbit calvarial intraosseous
defect model.Methods
Animals
Twenty male New Zealand white rabbits (age, 9–20
months; body weight, 3–3.5 kg) were used in this study.
The animals were housed in divided cages under stand-
ard laboratory conditions and fed a standard diet. The
selection of experimental animals, their management,
and the surgical protocol followed routines approved by
the Institutional Animal Care and Use Committee of
Yonsei Medical Center, Seoul, Korea.Materials
Large amounts of BMP-2 are difficult to purify or pro-
duce in vitro using eukaryotic cells. Human recombinant
BMP-2 produced in E. coli is a homodimeric, non-
glycosylated polypeptide containing 2 × 115 amino acids,
with a molecular mass of 26 kDa. The ErhBMP-2 used
in this study was provided by Daewoong Pharmaceutical
Co., Ltd. (Novosis®-dent, Gyeonggi, South Korea). Ly-
ophilized BMP-2 was dissolved in 10 cm3 of distilled
water to yield a concentration of 0.1 mg/mL. HAP, manu-
factured by BioAlpha Inc. (Bongros®, Gyeonggi, South
Korea), was used as the carrier material. Bongros® is com-
posed of pure HAP and has a particle diameter of 0.6–
1.0 mm. Bongros® was loaded with ErhBMP-2 by soaking
0.1 g of the material in 0.15 mL of ErhBMP-2 solution for
10 min. An ErhBMP-2 dose of 1.5 μg was achieved.Study design
Two circular calvarial intraosseous defects (8 mm in ex-
ternal diameter) were created side by side. Rabbits were
divided into two treatment groups: (1) HAP only and (2)
ErhBMP-2-loaded HAP (n = 10 animals per group). In
each animal, graft materials were grafted into one of the
defects, while the other defect was designated a sham
surgery control and was filled with blood clots alone.
The experimental sites for introduction of HAP or
ErhBMP-2-loaded HAP were randomly allocated. The
surgeon was not informed of the allocation until the de-
fects had been created.
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Rabbits were anesthetized with an intramuscular injec-
tion of a 4:1 solution of ketamine hydrochloride (Ketalar,
Yuhan, Seoul, Korea) and xylazine (Rompun, Bayer
Korea, Seoul, Korea). The surgical site was shaved and
disinfected with povidone iodine, and then infiltration
anesthesia was induced by injection of 2 % lidocaine
(lidocaine-HCl, Huons, Seoul, Korea). An incision was
made in the sagittal plane, and a full-thickness flap was
elevated. The two circular defects were then created in
each animal using 8-mm trephines under cool saline irri-
gation. The distance between the defects was 3 mm
(Fig. 1). The assigned graft material was grafted into one
of the defects. The soft tissue was repositioned and then
sutured layer-by-layer using 4–0 synthetic absorbable
multifilament suture materials (VicrylPlus Antibacterial,
Ethicon, Somerville, NJ, USA). Postoperative antibiotics
(gentamicin; 5 mg/kg body weight) were administered
by daily intramuscular injection for 1 week. The rabbits
were killed at either 2 weeks (n = 5 per group) or 8 weeks
(n = 5 per group) post-surgery.
Histological processing
Blocks that included the adjacent tissues were harvested.
The blocks were fixed in 10 % buffered formalin for
10 days, decalcified in 5 % formic acid for 14 days, and
then embedded in paraffin. Serial sections of 5-μm thick-
ness were cut. The two center-most sections were selected
from each block and stained with hematoxylin and eosin.
Evaluation methods
Clinical observation
Animals were carefully observed for inflammation, aller-
gic reactions, and other complications surrounding the
surgical site throughout the 2- and 8-week postoperative
healing periods.
Histological observation
Specimens were examined under a microscope (DM LB,
Leica Microsystems, Wetzlar, Germany) equipped with a
camera (DC300F, Leica Microsystems) by a single,Fig. 1 Two circular intraosseous defects of 8 mm diameter were made in eac
b, HAP only) were grafted into one defect, and the other defect was left untrblinded examiner. Images of the slides were acquired
and saved as digital files. Sections were examined at a
magnification of 40 × .Histomorphometric analysis
Histomorphometric data for the following parameters
were obtained with an automated image-analysis system
(Image-Pro Plus, Media Cybernetics, Silver Spring, MD,
USA; Figs. 2 and 3):
(1).Total augmented area (mm2): the area of all tissues
between the defect margins, including new bone,
connective tissue, and vessels
(2).New bone area (mm2): the area of newly formed
bone within the total augmented area; and
(3).Residual particle area (mm2): the area of HAP
remaining within the defect.Tomographic analysis
Specimens were scanned using a microcomputed tom-
ography (micro-CT) system (SkyScans1072, SkyScan,
Aartselaar, Belgium) at a resolution of 18 μm (100 kV
and 100 μA) (Figs. 4 and 5). The scanned sets of data were
processed in DICOM format, and the sum of the cross-
sectional view was used to reconstruct the area of interest
[15]. The overall dimensional topography of the recipient
beds was measured in the reconstructed views.Statistical analysis
Statistical analysis was performed using a commercially
available software program (SPSS 15.0, SPSS, Chicago, IL,
USA). Data from the histological and three-dimensional
micro-CT sections are presented as mean ± standard devi-
ation. The Kruskal–Wallis test was used to compare the
control, HAP only, and ErhBMP-2-loaded HAP groups.
The Mann–Whitney U test was used to compare samples
collected at 2 weeks and 8 weeks post-surgery. The level
for statistical significance was set at p < 0.05.h rabbit calvarium. The experimental graft materials (a, ErhBMP-2/HAP;
eated as a control
Fig. 2 Representative photomicrographs obtained at 2 weeks postoperation. a Control, b HAP only, c ErhBMP-2/HAP (hematoxylin and eosin, ×40).
Arrowheads = defect margin
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Clinical findings
All experimental sites showed uneventful healing dur-
ing the postoperative healing period. No evidence of
complications, such as abnormal bleeding, infection, or
exposure of graft materials, was observed. Signs of in-
flammation, such as swelling, were minimal, and the
grafted materials were confirmed to be intact within
the defects at the time of sacrifice and sample
collection.
Histological findings
After 2 weeks of healing, the sham surgery control de-
fects in the HAP only and ErhBMP-2/HAP groups
showed a small amount of wedge-shaped new bone for-
mation, limited to the defect margin. The amount of
newly formed bone in defects with grafted material was
greater in the ErhBMP-2/HAP group than in the HAP
only group. The center of control defects was depressed,
and thus flattened, by surrounding connective tissue anddura mater. In contrast, the center of HAP only and
ErhBMP-2/HAP defects was elevated by the grafted ma-
terial. New bone was formed at the defect margins
(Fig. 2). After 8 weeks of healing, the HAP only and
ErhBMP-2/HAP groups showed similar amounts of
newly formed bone (Fig. 3). More newly formed bone
was generated in the center of the defects during the 8-
week healing period than during the 2-week healing
period. The residual particle area was not reduced after
8 weeks of healing compared with 2 weeks of healing
(Figs. 2 and 3).
Histomorphometric findings
The histomorphometric measurements are summarized
in Tables 1, 2, and 3. The total augmented area was sig-
nificantly greater in the HAP only and ErhBMP-2/HAP
defects than in controls at 2 and 8 weeks (Fig. 6). Within
each group, no significant difference in total augmented
area was observed between 2 and 8 weeks (Table 1). At
2 weeks, the area of new bone differed significantly
Fig. 3 Representative photomicrographs obtained at 8 weeks postoperation. a Control, b HAP only, c ErhBMP-2/HAP (hematoxylin and eosin, ×40).
Arrowheads = defect margin
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(Table 2). The amount of residual material was similar
between HAP only and ErhBMP-2/HAP defects at 2 and
8 weeks (Table 3).
Tomographic analysis
The overall dimensional topography of the defects and
grafts was measured in reconstructed views at 2 and
8 weeks (Figs. 4 and 5). Newly formed bone was gray,
while HAP was white because of radiopacity. The total
augmented volume and new bone volume of each group
were measured using micro-CT (Tables 4 and 5). At 2
and 8 weeks, the total augmented volume was signifi-
cantly greater in the HAP only and ErhBMP-2/HAP
groups than in controls (Fig. 7). However, the total aug-
mented volume did not differ significantly between the
HAP only and ErhBMP-2/HAP groups at either 2 or
8 weeks (Table 4). At 2 and 8 weeks, the new bone vol-
ume was significantly greater in the HAP only and
ErhBMP-2/HAP groups than in controls (Fig. 7). At2 weeks, the new bone volume was significantly greater
in the ErhBMP-2/HAP group than in the other groups.
At 8 weeks, the difference in new bone volume between
the HAP only and ErhBMP-2/HAP groups was not sig-
nificant (Table 5).
Discussion
BMP is a key factor in bone regeneration and healing.
CHO BMP-2 is relatively expensive because of low pro-
duction volumes. ErhBMP-2 is particularly attractive for
biotechnology because of the ability of E. coli to grow
rapidly and at high density on inexpensive substrates.
Recombinant DNA techniques have been used to pro-
duce BMP-2 as an alternative to autograft bone to en-
hance healing of intraosseous defects.
Many studies have been performed to assess potential
rhBMP-2 carriers. Either platelet-rich plasma or calcium
phosphate can be used as a carrier of rhBMP-2 [16, 17].
The efficacy of an absorbable collagen sponge has also been
demonstrated [18, 19]. The Infuse® system (Medtronic,
Fig. 4 Representative coronally sectioned micro-computed tomography images at 2 weeks postoperation. a ErhBMP-2/HAP group, b HA only group
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collagen sponge carrier. OP-1® (Stryker Biotech, Kalamazoo,
MI, USA) consists of rhBMP-7 and bovine collagen that
has been reconstituted with saline to form a paste. How-
ever, collagen is not able to maintain space, which is crucial
for excluding unwanted cells. For space maintenance dur-
ing wound healing, biphasic calcium phosphate with a high
proportion of HA may be a more appropriate rhBMP-2
carrier [20]. Bioactive glass fabricated with dicalcium phos-
phate dehydrate is not suitable as a BMP-2 carrier; aFig. 5 Representative coronally sectioned micro-computed tomography imagprevious study showed that the bone mineral density, bone
area, and bone mineral content of tibiae and contralateral
femurs did not differ between control and BMP-treated
groups [21]. The goals of this study were to evaluate the
effect of HAP on bone regeneration and to determine the
efficacy of HAP as a carrier for ErhBMP-2 in a rabbit cal-
varial intraosseous defect model.
Collagen carriers do not resist collapse caused by soft
tissue pressure during bone formation. An investigation
of the bone cell response to titanium surfaces showedes at 8 weeks postoperation. a ErhBMP-2/HAP group, b HA only group
Table 1 Total augmented area of each group, as measured by
histomorphometric analysis
Total augmented area (mm2) 2 weeks (n = 10) 8 weeks (n = 10)
Control 6.34 ± 0.17 6.54 ± 0.32
HAP 9.51 ± 0.61* 8.64 ± 0.38*
ErhBMP-2/HAP 10.05 ± 0.52* 9.02 ± 0.55*
Values are means ± standard deviation; n = number of specimens
*Significant difference compared with control group (p < 0.05)
Table 3 Residual particle area of each group, as measured by
histomorphometric analysis
Residual particle area (mm2) 2 weeks (n = 10) 8 weeks (n = 10)
Control NA NA
HAP 1.99 ± 0.14 1.91 ± 0.38
ErhBMP-2/HAP 1.90 ± 0.34 1.82 ± 0.23
Values are means ± standard deviation; n = number of specimens
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of a BMP–atelopeptide type I collagen mixture [22]. An-
other study examined the effects of a BMP–atelopeptide
type I collagen mixture on bond strength at the interface
between bone and titanium implants. At 3 weeks post-
surgery, the reverse torque of the BMP-treated group
(74.2 ± 5.2 N · cm) was significantly greater than the re-
verse torque of the untreated group (32.8 ± 1.1 N · cm).
At 12 weeks post-surgery, the difference between the re-
verse torque of the BMP-treated group (89.2 ± 2.7 N ·
cm) and that of the untreated group (75.8 ± 2.4 N · cm),
although still statistically significant, was much smaller
[23]. These results are concordant with the results of the
present study, suggesting that the soaked carriers re-
leased the ErhBMP-2 early; this is a major limitation of
currently available carriers.
Our histomorphometric analyses showed that the
HAP only and ErhBMP-2/HAP groups had significantly
larger areas of new bone than the control group at
2 weeks post-surgery. The ErhBMP-2/HAP group also
differed significantly in new bone area from the control
and HAP groups. Surprisingly, although the ErhBMP-2/
HAP group showed a larger area of new bone than the
HAP only group at 2 weeks post-surgery, no significant
difference in new bone area was observed between the
ErhBMP-2/HAP and HAP only groups at 8 weeks post-
surgery. Thus, it can be inferred that the use of
ErhBMP-2 with HAP as the carrier promoted rapid ini-
tial bone regeneration. According to Zhu et al. [24], the
ability to repair bone defects decreases with time, al-
though Nano-HA/rhBMP-2 composite artificial bone
shows a good ability to repair bone defects.
Micro-CT images showed that the new bone volume
of the ErhBMP-2/HAP group was significantly larger
than that of the other groups at 2 weeks post-surgery.Table 2 New bone area of each group, as measured by
histomorphometric analysis
New bone area (mm2) 2 weeks (n = 10) 8 weeks (n = 10)
Control 1.25 ± 0.09 1.39 ± 0.13
HAP 2.94 ± 0.28* 3.68 ± 0.24*
ErhBMP-2/HAP 4.75 ± 0.50*† 3.67 ± 0.19*
Values are means ± standard deviation; n = number of specimens
*Significant difference compared with control group (p < 0.05)
†Significant difference between HAP and ErhBMP-2/HAP groups (p < 0.05)However, the ErhBMP-2/HAP and HAP only groups did
not differ significantly in new bone volume at 8 weeks
post-surgery. Consistent with this result, an in vitro
study showed that in the initial period of cultivation and
up to 72 h, coating of HAP with type I collagen had
positive effects on the viability and osteoblastic charac-
teristics of osteoblastic cells [25]. Therefore, it can be de-
duced that when guided bone regeneration is clinically
required, HAP soaked in ErhBMP-2 can be applied with-
out a membrane, since HAP can promote rapid initial
bone generation. This technique would be easier than
guided bone regeneration using an absorbable or non-
absorbable membrane and could provide quick and easy
promotion of rapid initial bone generation.
The total augmented area and volume did not differ
between the HAP only and ErhBMP-2/HAP groups at
8 weeks post-surgery. In addition, the residual particle
area did not differ significantly between 2 weeks and
8 weeks post-surgery. This indicates that HAP can main-
tain rigidity over a long period. The porous structure of
HAP facilitated the infiltration and adherence of respon-
sive cells, and the carrier itself became a component of
the newly formed bone. HAP is osteoconductive and can
maintain its original biocompatible form. Because of
these qualities, HAP may be useful in augmentation of
ridges and elevation of sinuses in clinical settings.
According to Lee et al. [26], there is a strong positive
correlation between a high concentration of rhBMP and
soft tissue swelling. It has been shown that the inflam-
matory response prompted by rhBMP lasts for only a
short period. Although it varies according to volume, the
degree of inflammation gradually decreases over the first
7 days; the authors therefore advise careful observation
for 7 days after surgery. In our experiment, no side ef-
fects, such as seroma or edema, were observed for up to
8 weeks. This indicates that the amount of ErhBMP-2
used in this experiment was not high enough to cause
serious side effects.
ErhBMP-2 is known to induce ectopic bone growth
[27]. If control and ErhBMP-treated bone defects are too
close together, ErhBMP-2 might flow into the control
defect and cause unwanted bone regeneration, seroma,
or edema [28]. In this study, no specific evidence of
complications was observed. In a previous study, doubts
were raised over whether a distance of 2 mm was
Fig. 6 Graphs showing histomorphometric analysis of total augmented area and new bone area (mm2). a Two weeks postoperation, b 8 weeks
postoperation. NA, new bone area; TA, total bone area
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affected by ErhBMP-2 in neighboring defects [29]. In
this study, a distance of 3 mm between the treated and
control defects proved to be sufficient to allow compari-
son of healing responses. Therefore, ErhBMP-2-loaded
HAP can be used as a graft material that does not affect
nearby defects.
Although new bone volume in the ErhBMP-2/HAP
group was rapidly promoted in the short term, it did not
increase over the long term. This may be due to theTable 4 Total augmented volume of each group, as measured
by tomographic analysis
Total augmented volume (mm3) 2 weeks (n = 10) 8 weeks (n = 10)
Control 5.78 ± 0.54 12.61 ± 1.16
HAP 56.31 ± 2.62* 72.66 ± 4.07*
ErhBMP-2/HAP 61.12 ± 1.84* 67.55 ± 5.48*
Values are means ± standard deviation; n = number of specimens
*Significant difference compared with control group (p < 0.05)limitations of HA as a carrier. According to Crouzier
et al. [30], ErhBMP-2 adsorbed onto polyelectrolyte
multilayer-coated films and, to a lesser extent, bare gran-
ules could be stored and remained bioactive for over
3 weeks. The in vivo release kinetics of BMP-2 from
calcium-deficient hydroxyapatite (CDHA) scaffolds re-
sembled the in vitro kinetics [31]. Similar observations
have been made in other ectopic and orthotopic animal
models [32]. Quantitative real-time PCR and enzyme-Table 5 New bone volume of each group, as measured by
tomographic analysis
New bone volume (mm3) 2 weeks (n = 10) 8 weeks (n = 10)
Control 5.78 ± 0.54 12.61 ± 1.16
HAP 28.40 ± 2.05* 40.60 ± 2.82*
ErhBMP-2/HAP 34.57 ± 1.65*† 38.31 ± 3.34*
Values are means ± standard deviation; n = number of specimens
*Significant difference compared with control group (p < 0.05)
†Significant difference between HAP and ErhBMP-2/HAP groups (p < 0.05)
Fig. 7 Graphs showing tomographic analysis of total augmented volume and new bone volume (mm3). a Two weeks postoperation, b 8 weeks
postoperation. NV, new bone volume; TV, total bone volume
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lized BMP-2/CDHA construct with trehalose (lyo-tre-
BMP-2) significantly promoted osteogenic differentiation
of bone marrow stromal cells [33]. The release rate of
BMP-2 is critical to bone regeneration. BMP-2 was
nearly 100 % released from lyo-tre-BMP-2 over 28 days.
Adsorption of BMP-2 onto HA follows the Langmuir
isotherm [34]. HAP may have more adsorption sites for
its high specific surface area than HA block bone.
Therefore, HAP may provide more opportunities for
binding of ErhBMP-2 molecules. To develop an effective
carrier, a method to release ErhBMP-2 from HAP at a
consistent rate is required. Once this problem is solved,
long-term increases in the volume and area of bone re-
generation are expected to be realized. In future work,
we will attempt to develop a method for slow, consistent
release of ErhBMP-2 during long-term healing. In
addition, other carriers, such as β-TCP, should be ana-
lyzed and compared.Conclusions
Combining ErhBMP-2 with HAP could significantly pro-
mote rapid initial new bone formation. Moreover, HAP
graft could increase new bone formation and space
maintenance, therefore it might be one of the effective
carriers of ErhBMP-2. Furthermore, in the future, the
identification of methods for slow and consistent release
of ErhBMP-2 during long-term healing will be needed.
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